专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20080213778A1 Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses 审中-公开
标题翻译：编码具有预后，诊断，预防，治疗和其他用途的蛋白质的新基因
公开(公告)号：US20080213778A1
公开(公告)日：2008-09-04
申请号：US11983233
申请日：2007-11-08
申请人： Douglas A. Holtzman , John D. Sharp , Kevin R. Leiby , Steven Bossone , Yang Pan , Thomas M. Barnes , Christopher C. Fraser , Nicholas Wrighton , Paul S. Myers , Gillian Kingsbury
发明人： Douglas A. Holtzman , John D. Sharp , Kevin R. Leiby , Steven Bossone , Yang Pan , Thomas M. Barnes , Christopher C. Fraser , Nicholas Wrighton , Paul S. Myers , Gillian Kingsbury
IPC分类号： C12N15/11 , C12N5/00 , C12N1/00 , C07K14/00 , C07K16/00 , C12P21/02 , G01N33/53 , C12Q1/68
CPC分类号： C07K14/7151 , A01K2217/05 , A61K38/00 , C07K14/47 , C07K14/705 , C07K14/78 , C07K2319/00 , Y10T436/143333
摘要： The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供了分离的TANGO 239，TANGO 219，TANGO 232，TANGO 281，A236（INTERCEPT 236），TANGO 300，TANGO 353，TANGO 393，TANGO 402，TANGO 351和TANGO 509核酸分子和多肽分子。本发明还提供反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞和其中引入了本发明的核酸分子的非人转基因动物，或中断了本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。还提供利用本发明组合物的诊断，筛选和治疗方法。

12. 发明授权

US06764677B1 Tango 294, a lipase-like protein 失效
标题翻译： Tango 294，脂肪酶样蛋白质
公开(公告)号：US06764677B1
公开(公告)日：2004-07-20
申请号：US09578063
申请日：2000-05-24
申请人： John D. Sharp , Thomas M. Barnes
发明人： John D. Sharp , Thomas M. Barnes
IPC分类号： A61K3843
CPC分类号： C07K14/47
摘要： The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
摘要翻译：本发明提供编码具有诊断，预防，治疗和其它用途的各种蛋白质的分离的核酸。这些核酸和蛋白质可用于诊断，预防和治疗许多人类和其他动物疾病。本发明还提供了反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞，以及引入了本发明的核酸分子的非人转基因动物，或中断了本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。还提供了利用本发明组合物的诊断，筛选和治疗方法。本发明的核酸和多肽可用作调节各种细胞过程的调节剂。

13. 发明申请

US20140341843A1 PURIFIED PROTEINS 审中-公开
标题翻译：纯化蛋白
公开(公告)号：US20140341843A1
公开(公告)日：2014-11-20
申请号：US14235777
申请日：2012-07-27
申请人： Thomas M. Barnes , Jinzhao Hou , Gregory Zarbis-Papastoitsis , Emily Belcher Schirmer , Gary L. McNeil , Kathryn Golden
发明人： Thomas M. Barnes , Jinzhao Hou , Gregory Zarbis-Papastoitsis , Emily Belcher Schirmer , Gary L. McNeil , Kathryn Golden
IPC分类号： C07K14/545 , B01D15/36
CPC分类号： C07K14/545 , A61K38/00 , B01D15/1864 , B01D15/362 , B01D15/363 , B01D15/3847 , C07K14/54 , Y02A50/473
摘要： The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions.
摘要翻译：本发明提供了用于制备和递送嵌合细胞因子蛋白质的方法和组合物，包括细胞培养物，纯化方法和纯化的组合物。

14. 发明授权

US5426044A Minactivin compositions and antibodies to minactivin 失效
标题翻译：灭活素组合物和灭活素的抗体
公开(公告)号：US5426044A
公开(公告)日：1995-06-20
申请号：US693636
申请日：1991-04-30
申请人： Toni M. Antalis , Thomas M. Barnes , Michelle A. Clark , Peter L. Devine , Neil H. Goss , Philip R. Lehrbach
发明人： Toni M. Antalis , Thomas M. Barnes , Michelle A. Clark , Peter L. Devine , Neil H. Goss , Philip R. Lehrbach
IPC分类号： G01N33/50 , A61K38/00 , A61K39/00 , A61K39/395 , A61P29/00 , A61P35/00 , C07H21/04 , C07K1/20 , C07K14/00 , C07K14/195 , C07K14/41 , C07K14/435 , C07K14/81 , C07K16/00 , C12N1/20 , C12N1/21 , C12N5/10 , C12N9/00 , C12N15/09 , C12P21/02 , C12Q1/68 , C12R1/19 , C12R1/91 , G01N33/53 , G01N33/577 , G01N33/58 , G01N33/86
CPC分类号： G01N33/86 , C07K14/8132 , A61K38/00 , G01N2333/811 , G01N2333/9723
摘要： A novel human protein, minactivin, can be produced by recombinant DNA technology, Biologically active native minactivin, peptides derived from minactivin, and their amino acid sequences can also be purified.
摘要翻译：可以通过重组DNA技术，生物活性天然灭活素，衍生自灭活素的肽，以及它们的氨基酸序列来纯化新的人蛋白质灭活素。

15. 发明申请

US20130209396A1 CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS 有权
标题翻译： CHIMERIC IL-1受体I型激动剂和拮抗剂
公开(公告)号：US20130209396A1
公开(公告)日：2013-08-15
申请号：US13812582
申请日：2011-07-29
申请人： Thomas M. Barnes , Jinzhao Hou , Bracken M. King
发明人： Thomas M. Barnes , Jinzhao Hou , Bracken M. King
IPC分类号： C07K14/545
CPC分类号： C07K14/545 , A61K38/00 , C07K2319/00 , Y02A50/463
摘要： Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, β strands, and loops from at least two parental cytokines domains.
摘要翻译：本文特征在于非天然存在的细胞因子结构域，其可以用于调节对白细胞介素-1受体I（IL-1RI）的响应的细胞信号传导，以治疗病症，以及检测和/或结合细胞受体，以及其他代理商。示例性细胞因子结构域可以包含来自至少两个亲本细胞因子结构域的氨基酸残基，例如受体结合特征，表面特征，β链和来自至少两个亲本细胞因子结构域的环。

16. 发明申请

US20080220495A1 DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof 审中-公开
标题翻译： DELTA3，FTHMA-070，TANGO85，TANGO77，SPOIL，NEOKINE，TANGO129和整合素α亚基蛋白和核酸分子及其用途
公开(公告)号：US20080220495A1
公开(公告)日：2008-09-11
申请号：US11974465
申请日：2007-10-12
申请人： Sean A. McCarthy , David P. Gearing , Douglas A. Holtzman , Yang Pan , Samantha J. Busfield , Thomas M. Barnes , Charles R. Mackay , Jose M. Lora
发明人： Sean A. McCarthy , David P. Gearing , Douglas A. Holtzman , Yang Pan , Samantha J. Busfield , Thomas M. Barnes , Charles R. Mackay , Jose M. Lora
IPC分类号： C12N11/00 , C07K16/00 , C07K17/00
CPC分类号： C12Q1/48 , A61K38/00 , C07K14/47 , C07K2319/00 , C12Q1/6876
摘要： The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供新颖的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259多肽，蛋白质和核酸分子。除了分离的全长Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259蛋白外，本发明还提供了分离的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259融合蛋白质，抗原肽和抗Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259抗体。本发明还提供了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞，已经引入或破坏了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129或A259基因的人类转基因动物。还提供利用本发明组合物的诊断，筛选和治疗方法。

17. 发明授权

US4105439A Method for production of refined steel 失效
标题翻译：精炼钢生产方法
公开(公告)号：US4105439A
公开(公告)日：1978-08-08
申请号：US801786
申请日：1977-05-31
申请人： Thomas M. Barnes
发明人： Thomas M. Barnes
IPC分类号： C21C5/56 , C21B3/04 , C21C5/28 , C21C5/32 , C21C5/36 , C21C7/072 , C21C5/00
CPC分类号： C21C5/28 , C21B3/04 , C21C5/32 , Y02W30/542
摘要： In a method of producing successive heats of refined steel wherein successive charges of molten, impure iron are refined by oxygen in the presence of at least one flux to form molten, refined steel and liquid slag, followed by the separation of said molten, refined steel and liquid slag, the improvement wherein a liquid slag from one of said refining operations is brought into contact with and caused to react with a batch of molten, impure iron which comprises a charge for a subsequent refining operation other than the immediate next successive refining operation to that from which the said liquid slag was obtained, such that at least some of the free and combined iron contained in said slag is substantially reduced and dissolved into said molten, impure iron, and such that the molten, impure iron is at least partially refined.
摘要翻译：在制造连续的精炼钢的方法中，其中在存在至少一种助熔剂的情况下，熔融的不纯铁的连续电荷被氧气精炼以形成熔融，精炼的钢和液态炉渣，然后将所述熔融精炼钢和液体炉渣，其中来自所述精炼操作之一的液体炉渣与一批熔融的不纯铁接触并引起与一批熔融的不纯铁反应的改进，其包括除了即时下一个连续精炼操作之外的后续精炼操作的装料获得所述液体渣的原料，使得所述炉渣中所含的游离和组合铁中的至少一些基本上被还原并溶解到所述熔融的不纯铁中，并且使得熔融的不纯铁至少部分地精制。

18. 发明申请

US20130064788A1 IL-17 FAMILY CYTOKINE COMPOSITIONS AND USES 审中-公开
标题翻译： IL-17家族细胞因子组合物和用途
公开(公告)号：US20130064788A1
公开(公告)日：2013-03-14
申请号：US13501244
申请日：2010-10-11
申请人： Thomas M. Barnes , Michael M. Schmidt , Bracken M. King , K. Christopher Garcia , Sashank Reddy , Gregory James Sieczkiewicz , Lauren K. Ely
发明人： Thomas M. Barnes , Michael M. Schmidt , Bracken M. King , K. Christopher Garcia , Sashank Reddy , Gregory James Sieczkiewicz , Lauren K. Ely
IPC分类号： A61K38/20 , C12P21/02 , C12N5/10 , C12N1/21 , A61P29/00 , C12N1/19 , C07K14/54 , C07K16/24 , C07H21/04 , A61P37/02 , A61K39/395 , C12N1/15
CPC分类号： C07K14/54 , C07K14/7155
摘要： Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL-17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.
摘要翻译：结合蛋白质，包括结合IL-17R的非天然存在和重组修饰的蛋白质，并且包括具有突变的IL-17细胞因子序列的蛋白质，制备这种分子的方法和使用这些分子作为治疗剂，预防剂和诊断剂的方法是提供。

19. 发明申请

US20090286956A1 DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof 有权
标题翻译： DELTA3，FTHMA-070，TANGO85，TANGO77，SPOIL，NEOKINE，TANGO129和INTEGRIN ALPHA SUBUNIT蛋白质和核酸分子及其用途
公开(公告)号：US20090286956A1
公开(公告)日：2009-11-19
申请号：US11974478
申请日：2007-10-12
申请人： Sean A. McCarthy , David P. Gearing , Douglas A. Holtzman , Yang Pan , Samantha J. Busfield , Thomas M. Barnes , Charles R. Mackay , Jose M. Lora
发明人： Sean A. McCarthy , David P. Gearing , Douglas A. Holtzman , Yang Pan , Samantha J. Busfield , Thomas M. Barnes , Charles R. Mackay , Jose M. Lora
IPC分类号： C07K14/705
CPC分类号： C12Q1/48 , A61K38/00 , C07K14/47 , C07K2319/00 , C12Q1/6876
摘要： The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供新颖的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259多肽，蛋白质和核酸分子。除了分离的全长Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259蛋白外，本发明还提供了分离的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259融合蛋白质，抗原肽和抗Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259抗体。本发明还提供了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259核酸分子，含有本发明的核酸分子的重组表达载体，已经引入表达载体的宿主细胞，已经引入或破坏了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129或A259基因的人类转基因动物。还提供利用本发明组合物的诊断，筛选和治疗方法。

20. 发明授权

US5422090A Human PAI-2 失效
标题翻译：人PAI-2
公开(公告)号：US5422090A
公开(公告)日：1995-06-06
申请号：US911531
申请日：1992-07-15
申请人： Ross W. Stephens , Jeffrey P. Golder , Toni M. Antalis , Thomas M. Barnes , Michell A. Clark , Peter L. Devine , Neil H. Goss , Philip R. Lehrbach
发明人： Ross W. Stephens , Jeffrey P. Golder , Toni M. Antalis , Thomas M. Barnes , Michell A. Clark , Peter L. Devine , Neil H. Goss , Philip R. Lehrbach
IPC分类号： A61K38/00 , C07K14/81 , G01N33/574 , G01N33/86 , C07K14/00
CPC分类号： C07K14/8132 , G01N33/574 , G01N33/86 , A61K38/00 , G01N2333/811 , G01N2333/8132 , G01N2333/9723
摘要： Minactivin (also known as Plasminogen Activator Inhibitor-2 [PAI-2]), a protein inactivator of urokinase-type plasminogen activator, has been shown to be a natural inactivator of this plasminogen activator which is associated with invasive tumors, and is therefore indicated as a crucial element in the body's normal defense against tumor invasion and metastasis. It may be produced by the cultivation of minactivin-producing cells in vitro, and recovery of the cell culture supernatant. By controlling the culture conditions, the protein minactivin may be produced in a partially purified form which may be used for diagnosis and treatment of tumors. The specification discloses purification of biologically active native minactivin, as well as peptides derived from minactivin and their amino acid sequences. The specification also discloses methods for production of PAI-2 by recombinant DNA technology, characterization of a PAI-2 gene sequence, and expression and purification of large quantities of biologically active PAI-2 from a recombinant host.
摘要翻译：已经显示，灭活素（也称为纤溶酶原激活物抑制剂-2 [PAI-2]）是尿激酶型纤溶酶原激活物的蛋白质灭活剂，其是与侵袭性肿瘤相关的该纤溶酶原激活物的天然灭活剂，因此被指示作为人体正常防御肿瘤侵袭转移的关键因素。可以通过体外灭活生成细胞的培养和细胞培养上清液的回收来产生。通过控制培养条件，蛋白质灭活素可以以可用于诊断和治疗肿瘤的部分纯化形式产生。本说明书公开了生物活性天然灭活素的纯化，以及衍生自灭活素及其氨基酸序列的肽。该说明书还公开了通过重组DNA技术生产PAI-2的方法，PAI-2基因序列的表征，以及来自重组宿主的大量生物活性PAI-2的表达和纯化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式